Activity and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: a biomarker-driven phase II study.

Nom du journal : Clin Cancer Res

Année : 2019

Volume : 25

Page de départ : 4611

Page de fin : 4615

Auteurs: Esnaud T, Boidot R, Ghiringhelli F, Mir O, Le Loarer F, Toulmonde M, Bouché O, Bompas E, Lucchesi C, Italiano A, Bellera CA, Duffaud F, Isambert N, Penel N, Blay JY, Geneste D,